 |
|
|
| |
HIV-1 Attachment Inhibitor Prodrug BMS-663068:
Interactions with Rifabutin, with or without Ritonavir, in Healthy Subjects
|
| |
| |
Reported by Jules Levin
IAS 2015 Vancouver July 19-23
8th IAS Conference on HIV Pathogenesis, Treatment and Prevention
R Adamczyk,1 A Griffies,1 P Ravindran,1 C Smith,2 J Anderson,1 D W Boulton,1* I Landry1
1Bristol-Myers Squibb, Research and Development, Princeton, NJ, USA; 1*Formerly at Bristol-Myers Squibb, Research and Development, Princeton, NJ, USA. Current employee of AstraZeneca, Gaithersburg, MD, USA; 2PPD, Richmond, VA, USA
FOLLOWING THESE LINKS IS DATA FROM IAS RIFABUTIN INTERACTION STUDY
IAS: HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Analysis of Emergent Viral Drug Resistance Through 48 Weeks of Follow-Up - (07/24/15)
IAS: Second-Generation HIV-1 Maturation Inhibitor BMS-955176: Antiviral Activity and Safety with Atazanavir ± Ritonavir - (07/22/15)
Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 48 Analysis......http://www.natap.org/2015/CROI/croi_38.htm
Absence of renal and bone toxicity in non-clinical studies of BMS-986001, a nucleoside reverse transcriptase inhibitor (NRTI) of human immunodeficiency virus (HIV) - (07/25/12)
THE HIV NRTI BMS-986001 DOES NOT DEGRADE MITOCHONDRIAL DNA IN LONG TERM PRIMARY CULTURES OF CELLS ISOLATED FROM HUMAN KIDNEY, MUSCLE AND SUBCUTANEOUS FAT - (07/25/12)
Early studies - Pharmacodynamics, Safety, and Pharmacokinetics of BMS-663068, an Oral HIV-1 Attachment Inhibitor in HIV-1-Infected Subjects.......http://www.natap.org/2012/HIV/090712_02.htm
HIV-1 Attachment Inhibitor Prodrug BMS-663068:
Pharmacokinetics, Pharmacodynamics and Model-Based Dose Selection.......http://www.natap.org/2015/CROI/croi_24.htm
ClinPharmWk/2015: HIV-1 Attachment Inhibitor Prodrug BMS-663068: Assessment of Interactions with
Raltegravir in Treatment-Experienced HIV-1-Infected Subjects & Efficacy/Safety......http://www.natap.org/2015/Pharm/Pharm_29.htm
CROI: HIV-1 Attachment Inhibitor Prodrug BMS-663068: Interactions with DRV/r and/or ETR - (02/26/15)
CROI: 48-Week Analysis of Investigational HIV-1 Attachment Inhibitor Paves Way for Phase III Trial Initiation - (03/03/15)
Phase III trial now underway for novel therapy for heavily treatment-experienced HIV-1 patients
Binding directly to the HIV virus, BMS-663068 is the first investigational antiretroviral designed to prevent initial viral attachment to host CD4+ T cells and entry into host immune cells
HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Subgroup Analysis and Safety Profile - oral presentation.......http://www.natap.org/2014/GLASGOW/GLASGOW_16.htm
|
| |
|
|
|
|
|
